Zobrazeno 1 - 10
of 12
pro vyhledávání: '"F. E. De Jongh"'
Autor:
I. E. de Kruijff, A. M. Sieuwerts, N. Beije, W. J. C. Prager - van der Smissen, L. Angus, C. M. Beaufort, M. N. Van, E. Oomen - de Hoop, A. Jager, P. Hamberg, F. E. de Jongh, J. Kraan, J. W. M. Martens, S. Sleijfer
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundCisplatin (cDDP) has regained interest for metastatic breast cancer (MBC) patients, given the platinum sensitivity in subtypes and better manageable toxicity. Here, the primary aim was to determine whether molecular characteristics of circu
Externí odkaz:
https://doaj.org/article/3ecfd168a49445039557708262e8b2a4
Autor:
F. E. de Jongh, Nicolai Maass, Martin Andersson, Tanja Cufer, Valentina Nekljudova, Robert Stein, E. Maartense, G. von Minckwitz, Jana Barinoff, Klaus Baumann, Christoph Mundhenke, Martina Schmidt, H.-J. Lück, Joyce Bischoff, Nadia Harbeck, Christoph C. Zielinski, S. Loibl, K. Schwedler
Publikováno v:
Cancer Research. 70:P6-14
Background: In women with HER2-positive breast cancer progressing during trastuzumab treatment, continuation of trastuzumab plus capecitabine (XH) showed a significantly improved overall response rate and time to progression compared with capecitabin
Autor:
John W.M. Martens, Anieta M. Sieuwerts, Jaco Kraan, J Bolt-de Vries, P. van der Spoel, Agnes Jager, Bianca Mostert, Marcel Smid, A van Galen, Dieter Peeters, Caroline M. Seynaeve, Stefan Sleijfer, J.A. Foekens, Jan-Willem Gratama, F. E. de Jongh, Jacqueline M. Stouthard, Diederik F. S. Kehrer, Maxime P. Look, Luc Dirix, P. Hamberg
Publikováno v:
Annals of oncology
Annals of Oncology, 26(3), 510-516. Elsevier Ltd.
Annals of Oncology, 26(3), 510-516. Elsevier Ltd.
Background: A circulating tumor cell (CTC) count is an established prognostic factor in metastatic breast cancer (MBC). Besides enumeration, CTC characterization promises to improve outcome prediction and treatment guidance. Having shown the feasibil
Publikováno v:
European Journal of Endocrinology. :221-226
OBJECTIVE: Non-thyroidal illness (NTI) is associated with alterations in thyroid hormone metabolism. Whether morphological changes of the thyroid gland accompany NTI is unknown. The aim of the present study was to describe thyroid morphology in patie
Publikováno v:
BMJ Case Reports. :bcr2015213624
Sunitinib is a tyrosine kinase inhibitor that is used as an anticancer drug in renal cell carcinoma (RCC), pancreatic neuroendocrine tumours (PNETs) and gastrointestinal stromal tumour. Elevated liver enzymes are frequently observed during treatment
Autor:
K E, Verweij, F E, de Jongh
Publikováno v:
The Netherlands journal of medicine. 69(10)
Autor:
F E, de Jongh, R, de Wit, J, Verweij, A, Sparreboom, M J, van den Bent, G, Stoter, M E L, van der Burg
Publikováno v:
European journal of cancer (Oxford, England : 1990). 38(15)
A randomised phase I/II trial with weekly cisplatin 70 mg/m(2) (days 1, 8, 15, 29, 36, 43) in combination with escalating doses of paclitaxel either 4-weekly or weekly was conducted in 49 patients with ovarian cancer; patients were chemotherapy-nai;v
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 140(1)
A 45-year-old woman in the period 1988-1995 suffered three episodes of acute pancreatitis associated with the use of metronidazole. On each occasion the pancreatitis subsided after withdrawal of metronidazole. Pancreatitis is a very infrequent, but p
Autor:
R.H.N. van Schaik, F. E. de Jongh, F.Y. de Vos, A.J. de Graan, S.F. Teunissen, Walter J. Loos, Jaap Verweij, Caroline Seynaeve, Ron H.J. Mathijssen, J. H. Beijnen
Publikováno v:
European Journal of Cancer Supplements. 8:204
Publikováno v:
The American journal of gastroenterology. 86(8)
Between 1974 and 1989, 411 patients with pathologically and anatomically proven carcinoma of the head of the pancreas underwent endoscopic retrograde cholangiopancreatography (ERCP). According to the localization of the tumor, these patients were div